Marc Y Donath

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes
    Claudia Cavelti-Weder
    Department of Endocrinology, Diabetes, and Metabolism, University Hospital Basel, Basel, Switzerland
    Diabetes Care 35:1654-62. 2012
  2. ncbi IL-1β activation as a response to metabolic disturbances
    Marc Y Donath
    University Hospital Basel, Switzerland
    Cell Metab 12:427-8. 2010
  3. ncbi Type 2 diabetes as an inflammatory disease
    Marc Y Donath
    Clinic of Endocrinology, Diabetes and Metabolism, University Hospital Basel, CH 4031 Basel, Switzerland
    Nat Rev Immunol 11:98-107. 2011

Collaborators

  • Charles A Dinarello
  • Claudia Cavelti-Weder
  • Hany Zayed
  • Alan M Solinger
  • Andrea Babians-Brunner
  • Malaika Kurz-Levin
  • Thomas Mandrup-Poulsen
  • Marc A Stahel
  • Cornelia Keller

Detail Information

Publications3

  1. ncbi Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes
    Claudia Cavelti-Weder
    Department of Endocrinology, Diabetes, and Metabolism, University Hospital Basel, Basel, Switzerland
    Diabetes Care 35:1654-62. 2012
    ..Gevokizumab is a novel, human-engineered monoclonal anti-IL-1β antibody. We evaluated the safety and biological activity of gevokizumab in patients with type 2 diabetes...
  2. ncbi IL-1β activation as a response to metabolic disturbances
    Marc Y Donath
    University Hospital Basel, Switzerland
    Cell Metab 12:427-8. 2010
    ..A recent report in Nature Immunology (Masters et al., 2010) identifies amyloid polypeptide as an additional enhancer of IL-1β production...
  3. ncbi Type 2 diabetes as an inflammatory disease
    Marc Y Donath
    Clinic of Endocrinology, Diabetes and Metabolism, University Hospital Basel, CH 4031 Basel, Switzerland
    Nat Rev Immunol 11:98-107. 2011
    ....